☆ 4.6 Article

Abstract A216: Results of a phase 1, open-label, dose-escalation study evaluating the safety and tolerability of EZN-3042, a survivin mRNA antagonist, administered with docetaxel (D) in adult patients (Pts) with advanced solid tumors.

MOLECULAR CANCER THERAPEUTICS (2012)

Get Full Text
Add to Collection

Journal

MOLECULAR CANCER THERAPEUTICS
Volume 10, Issue Supplement 1, Pages A216-A216

Publisher

American Association for Cancer Research (AACR)
DOI: 10.1158/1535-7163.targ-11-a216

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.